Novartis’s NASH Chief: Our Strategy Is Combos With Tropifexor As ‘Backbone’
Novartis's broad but early-stage NASH pipeline will use FXR agonist tropifexor as its keystone for developing combination therapies with outside partners.
Novartis's broad but early-stage NASH pipeline will use FXR agonist tropifexor as its keystone for developing combination therapies with outside partners.